At the core of the drug discovery process is the screening of hundreds of thousands of compounds in a high-throughput manner using in-vitro assays. Time-sensitive and cost-effective strategies are crucial for the identification of valuable hits with a specific pharmacological activity, such as those modulating a target or a cellular pathway of interest.
At Axxam, we support our clients during the early phases of the drug discovery process, from assay design to the performance of High-Throughput Screening (HTS) campaigns, and even further during the Hit-to-Lead process. Our expertise enables us to develop the most suitable hit-identification strategy, ensuring a reliable compound class that can be pursued for further drug development.
We not only find the needles, but also sort the haystack!
The fundamental ingredients for a successful hit discovery program are meaningful assays, high quality compound libraries and well planned screening campaigns. To run an HTS campaign, clients can access our assay development services, select one of our ready-to-use assays or transfer their own validated assays to us. We carry out hit-discovery programs using either compound collections available at Axxam or our clients’ preferred libraries, which are handled securely at our facility. Besides small molecules, we also screen chemical mixtures, natural product extracts, oligonucleotides, and antibodies. The most appropriate screening strategy is selected for any screening campaign according to the specific target’s characteristics. This approach ensures the highest probability for a successful HTS with meaningful results, providing the foundation to generate innovative lead compounds.
HTS platforms & technologies
We provide access to fully automated, state-of-the-art screening platforms designed to run cell-free and cell-based assays in a miniaturized format using a variety of detection technologies such as luminescence, fluorescence (intensity polarization, time-resolved such as HTRF or LANCE, calcium flux, membrane potential, thallium flux), absorbance, as well as radiometric measurement using ligand-binding, scintillation proximity assays (SPA), flashplate assays and transporter assays.
Cell-based screenings can also be performed using electrophysiological, quantitative genetic expression, and phenotypic imaging-based readouts.